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Abstract 
Complex forming capabilities of [(6-p-cymene)Ru(H2O)3]2+ with aminohydroxamates (2-
amino-N-hydroxyacetamide (-alahaH), 3-amino-N-hydroxypropanamide (-alahaH) and 4-
amino-N-hydroxybutanamide(-abhaH)) having the primary amino group in different 
chelatable position to the hydroxamic function were studied by pH-potentiometry, NMR and 
MS methods. Formation of stable [O,O] and mixed [O,O][N,N] chelated mono- and dinuclear 
species is detected in partially slow with -alahaH and -alahaH or in fast processes with -
abhaH and the formation constants of the complexes present in aqueous solution are reported. 
Synthesis, spectral (NMR, IR) and ESI mass spectrometric characterization of novel dinuclear 
-alaninehydroximato complexes containing the half-sandwich type Ru(II) core is described. 
The crystal and molecular structure of [{(6-p-cymene)Ru}2(2--alahaH–1)(H2O)Br]Br∙H2O 
(1) and [{(6-p-cymene)Ru}2(2--alahaH–1)(H2O)Cl]BF4∙H2O (2) was determined by single 
crystal X-ray diffraction method. In the complexes one half-sandwich core is coordinated by a 
hydroxamate [O,O] chelate while the other one by [Namino,Nhydroxamate] fashion of the bridging 
ligand. In both cases the remaining coordination sites of one of the Ru cores are taken by a 
halide ion whiles the other one by a water molecule. Reaction of 2 with 9-methylguanine 
indicates the N7 coordination of this simple DNA model. Complexes 1 and 2 were tested for 
their in vitro cytotoxicity using human-derived cancer cell lines (A2780, MCF-7, SKOV-3, 
HCT116, HeLa) and showed no anti-proliferative activity in the micromolar concentration 
range. 
                                               
* Corresponding author: buglyo@science.unideb.hu, phone number: + 36 52 512900/22305. 
2 
 
 
1. Introduction 
Hydroxamic acids with the general formula of R1(CO)N(R2)OH are important class of 
biomolecules and are attracting an increasing attention. They are known, for example, as 
constituents of siderophores and enhance the uptake of various metal ions (e.g. Fe3+) in 
microorganisms.[1-3] Hydroxamates are also considered as effective inhibitors of various 
metalloenzymes.[3-4]  Both type of biological activity is obviously connected to their capability 
of forming stable five-membered [O,O] chelate(s) with various, mostly hard type metal ions. 
Based on the inhibition of a Zn(II)-containing metalloenzyme, histone deacetylase, a 
monohydroxamic acid, suberoylhydroxamic acid (SAHA), is currently undergoing clinical use 
as a treatment for cutaneous T-cell lymphoma.[5]  
Half-sandwich type Ru(II) complexes with promising anti-proliferative properties are 
also in the focus of intensive research in recent decades. Earlier studies mostly dealt with the 
design, synthesis, characterization and biological test of these [(η6-arene)Ru(XY)Z] type (arene 
= benzene(derivative), XY = chelating, Z = monodentate ligand) complexes.[6-10] Recent years  
research focusing on their solution behaviour or the interaction with various high[11-17] or low 
molecular mass[18-29] biomolecules is also in progress. 
Lately we have combined hydroxamates and half-sandwich [(η6-p-cym)M]2+ (p-cym = 
p-cymene = 1-methyl-4-(1-methylethyl)benzene; M = Ru, Os) entities, both having potential 
biological activity, into one molecule hoping to obtain compounds with beneficial features.[18,30] 
Although detailed solution equilibrium studies revealed that monohydroxamates are capable of 
binding [(η6-p-cym)Ru(H2O)3]2+ in stable complexes over a wide pH-range in aqueous solution, 
biological tests on human-derived ovarian cancer cell lines (A2780 and A2780 cisR) indicated 
no improved biological activity. The lack of antiproliferative activity of these compounds was 
interpreted in terms of labile behaviour of the [O,O] chelate formed despite the high 
thermodynamic stability of the complexes.[18] 
Presence of Ru-Namino bond(s) in [(η6-arene)Ru(XY)Z] complexes seems to result in 
more inert behaviour.[31] Hydroxamate derivatives of simple amino acids also bear a primary 
amino group beside the hydroxamic function therefore may represent ligands with beneficial 
binding properties for [(η6-p-cym)Ru(H2O)3]2+ in terms of the appropriate kinetic inertness. 
Aminohydroxamates have been shown to act as exclusive [O,O] chelators for hard metal ions 
(Fe3+, Al3+) but soft metal ions were found to have a preference for [N,N] coordination in the 
basic pH-range with the involvement of the hydroxamate-N of primary hydroxamates in metal 
ion binding.[32-37] For borderline metal ions (e.g. Cu2+) the formation of stable pentanuclear 
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metallacrowns with the parallel coodination of both types of the donor sets of – or –
aminohydroxymates was detected both in solution and in the solid state.[38-39] 
In the present work, we sought to gain a deeper insight into the effect of the presence of 
the terminal amino group beside the hydroxamate function on the [(η6-p-cym)Ru(H2O)3]2+ ion 
binding in solution and its role on the stability, stoichiometry, nuclearity and binding 
architecture of the half-sandwich type Ru(II) aminohydroxamate complexes. 
Herein we report on the results of a solution equilibrium study relating the interaction 
of [(η6-p-cym)Ru(H2O)3]2+ with 2-amino-N-hydroxyacetamide (-alahaH), 3-amino-N-
hydroxypropanamide (-alahaH) and 4-amino-N-hydroxybutanamide(-abhaH) (Fig. 1) 
obtained by the combined use of pH-potentiometry, NMR and ESI-MS together with the 
synthesis, characterization, biological test and 9-methylguanine (as a simple DNA model) 
binding capabilities of [{(6-p-cym)Ru}2(2--alahaH–1)(H2O)Br]Br∙H2O (1) and [{(6-p-
cym)Ru}2(2--alahaH–1)(H2O)Cl]BF4∙H2O (2) complexes.    
      
2. Experimental  
 
Materials and methods 
RuCl3.xH2O, α-terpinene, AgNO3, O-benzylhydroxylamine hydrochloride, N-
carbobenzyloxy-γ-aminobutanoic acid, ethylchloroformate, N-methylmorpholine, Pd/C (10 
%), KBr and NaBF4, 9-methylguanine of highest purity were all commercial products (Merck, 
Aldrich, and Reanal) and used as received. CH3OH, CH2Cl2 and THF, used for the preparation 
of the ligands, were purchased from Molar chemicals. Hydroxylamine hydrochloride was 
purified by recrystallization.[40] -AlahaH and -alahaH∙HCl were synthesized using a 
published method.[41] [(η6-p-cym)RuCl2]2 was synthesized and purified according to a literature 
procedure.[42] Aqueous solution of [(η6-p-cym)Ru(H2O)3](NO3)2 was obtained from [(η6-p-
cym)RuCl2]2 by the removal of chloride ion using equivalent amount of silver nitrate. 1H NMR 
spectra were recorded on a Bruker Avance 360 or 400 NMR spectrometer at room temperature 
in D2O or CDCl3 and referenced to 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt (TSP) 
or to the 1H resonances of the residual solvents. ESI-TOF MS measurements in the positive 
mode were carried out on a Bruker micrOTOF-Q instrument. IR spectra as KBr pellets were 
recorded on a Perkin Elmer FTIR Paragon 1000 PC instrument. Elemental analyses were 
conducted on Elementar Vario MICRO CUBE instrument at the Department of Organic 
Chemistry, University of Debrecen, Hungary.  
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Crystal structure analysis  
Diffraction intensity data collection was carried out at 100 K on a SuperNova diffractometer 
equipped with an Atlas detector using Cu-Kα radiation (λ = 1.5418 Å). The structure was solved 
by SIR-92 program[43] in centrosymmetric space group P-1 (No.2) as it is usually expected for 
a racemic compound and refined by full-matrix least-squares method on F2. Non-hydrogen 
atoms were refined anisotropically using the SHELX package[44] except one fluorine of the 
tetrafluoroborate anion in structure 2. Publication material was prepared with the WINGX- 
suite[45] and publCIF[46]. In structure 2 the BF4– counter ion and the methyl groups of the i-Pr 
moiety of one of the p-cymene ligands are disordered over two positions with occupancy of ca. 
68:32 ratio. Hydrogen atoms were treated with a mixture of independent and constrained 
refinement. C-H and N-H hydrogen atoms were placed into geometric position and methyl 
groups were refined using a riding model. Hydrogen atoms of water molecules were found at 
the difference electron density map but the distances of hydrogen and oxygen atoms should be 
restrained in the final stage of the refinement. Still the orientation of water molecules is 
ambiguous but presence of heavy atoms prevents more exact determination of place of 
hydrogen atoms and orientation of water molecules. This ambiguities resulted B and C level 
errors in donor-hydrogen distances, as detected by the checkcif facility, but they do not 
influence the overall correctness of the structures. Crystallographic and experimental details are 
summarized in Table 1. The remaining peaks at the difference electron density maps are located 
close to the ruthenium atoms. All the crystallographic data for 1 and 2 are deposited in the 
Cambridge Crystallographic Data Centre under CCDC 1423422-1423423. 
 
Preparation of the ligands and complexes  
 
Benzyl(N-carbobenzyloxy)-γ-aminobutanehydroxamate 
O-benzylhydroxylamine hydrochloride (4.07 g, 25 mmol) was dissolved in dry methanol (40 
ml) and chilled in an ice-bath under nitrogen. KOH (1.4 g, 25 mmol) as pellets, was added to 
the solution and the mixture was stirred in ice-bath for 10 min meanwhile solid KCl formed. In 
another flask N-carbobenzyloxy-γ-aminobutanoic acid (4.0 g, 17 mmol) was dissolved in dry 
THF (50 ml) under nitrogen and cooled to 0 °C in ice-bath.  Ethylchloroformate (2.0 ml, 21 
mmol) followed by N-methylmorpholine (2.4 ml, 22 mmol) were added while stirring. The 
reaction mixture was stirred for 40 min under inert conditions, white precipitate (N-
methylmorpholinium chloride) formed. The free O-benzylhydroxylamine solution was filtered 
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into a three-neck flask while the solution of the mixed anhydride filtered into a dropping funnel. 
The latter solution was added dropwise to the former within 5 min while stirring under nitrogen 
at 0 °C. The resulting reaction mixture was stirred overnight under nitrogen at room 
temperature. Next day the solvent was evaporated from the milky-like reaction mixture and the 
remaining solid was dissolved in CH2Cl2 (100 ml). It was extracted with 0.5 M aqueous citric 
acid solution (3x30 ml) and saturated NaHCO3 solution (2x25 ml). The extract was washed 
with 25 ml water, then dried on MgSO4 and evaporated in vacuo. The pure product was obtained 
as a white solid after recrystallization from 30 ml ethyl acetate. Yield: 4.31 g (75 %). 1H NMR 
(360 MHz, CDCl3, 298 K): δ = 1.81 m [-CH2]; 2.08 m [-CH2]; 3.20 m [-CH2]; 4.93 s [-CH2]; 
5.07 s [-CH2]; 7.34 m [Ar (-H)].  
 
4-amino-N-hydroxybutanamide hydrochloride (-abhaH·HCl) 
In a two-neck flask benzyl(N-carbobenzyloxy)-γ-aminobutanehydroxamate (1.0 g, 2.9 mmol) 
was dissolved in dry ethyl acetate (35 ml) under nitrogen. Pd/C (10 %, 0.20 g) and methanolic 
solution of HCl (2.6 M, 1.12 ml) was added and the suspension was stirred under H2 atmosphere 
at room temperature. After 4.5 h the catalyst was filtered off and washed with methanol (3x15 
ml). The resulting solution was evaporated and the oily product was dried in vacuo. Yield: 0.39 
g (87 %). 1H NMR (360 MHz, D2O, 298 K): δ = 1.93 m [-CH2]; 2.26 t [-CH2]; 3.00 t [-CH2].  
 
[{(6-p-cym)Ru}2(2--alahaH–1)(H2O)Br]Br·H2O (1)  
[(η6-p-cym)RuCl2]2 (61.16 mg, 0.09987 mmol) and α-alahaH (11.79 mg, 0.1010 mmol) was 
dissolved in water (2 ml) and stirred for 1 h. The pH of the solution was set to pH ~ 5 with a 
few drops of concentrated fresh carbonate-free NaOH solution and stirred for another 2 h. The 
resulting red solution was filtered off and KBr (48.70 mg, 0.4092 mmol) was added. On cooling 
to 4 oC, the red crystalline solid was separated which was filtered, washed with dry diethyl ether 
and dried in vacuum. Yield: 42.20 mg (55 %). Calcd. for C23H38N2O4Ru2Br2: C, 35.95; H, 4.98; 
N, 3.65; found C, 35.69; H, 5.08; N, 3.67. 1H NMR (400 MHz, D2O, 298 K): δ = 1.25 m [12H, 
-CH(CH3)2 (p-cym)] and [3H, -CH3 (α-Alaha)]; 2.21 s, 2.23 s [6H, -CH3 (p-cym)]; 2.77 m, 2.85 
m [2H, -CH(CH3)2 (p-cym)]; 3.38 m [1H, -CH (α-Alaha)]; 5.47 d, 5.53 d, 5.69 d, 5.74 d, 5.55 
m, 5.64 m, 5.78 m [8H, Ar(-H)]. IR (KBr): νmax/cm-1 = 3380 br (O-H), 2961 s (C-H), 2927 s 
(C-H), 2871 s (C-H), 1578 s (C=O). MS (ESI-TOF): m/z = 652.983 [((η6-p-cym)Ru)2(α-
alahaH‒1)(Br)]+ (simulated = 652.989).  
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[{(6-p-cym)Ru}2(2--alahaH–1)(H2O)Cl]BF4·H2O (2)  
[(η6-p-cym)RuCl2]2 (61.20 mg, 0.09994 mmol) and α-alahaH (11.70 mg, 0.1002 mmol) was 
dissolved in water (3 ml) and stirred for 1 h. The pH of the solution was set to pH ~ 5 with a 
few drops of concentrated fresh carbonate-free NaOH solution and stirred for 90 min. The 
resulting red solution was filtered and NaBF4 (22.00 mg, 0.2004 mmol) was added. The solution 
was then cooled to 4 oC, the red crystalline complex obtained was filtered, washed with dry 
diethyl ether and dried in vacuum for 10 min. Yield: 38.29 mg (52 %). Calcd. for 
C23H38N2O4Ru2ClBF4: C, 37.79; H, 5.24; N, 3.83; found C, 37.67; H, 5.36; N, 3.87. 1H NMR 
(360 MHz, D2O, 298 K, TSP): δ = 1.25 m [12H, -CH(CH3)2 (p-cym)] and [3H, -CH3 (α-Alaha)]; 
2.21 s [6H, -CH3 (p-cym)]; 2.80 m [2H, -CH(CH3)2 (p-cym)]; 3.38 m [1H, -CH (α-Alaha)]; 5.45 
d, 5.52 d, 5.56 d, 5.63 d, 5.67 d, 5.73 d, 5.78 d, 5.83 d [8H, Ar(-H)]. IR (KBr): νmax/cm-1 = 3384 
br (O-H), 2963 s (C-H), 2930 s (C-H), 2873 s (C-H), 1578 s (C=O), 1060 br (B-F). MS (ESI-
TOF): m/z = 609.040 [((η6-p-cym)Ru)2(α-alahaH‒1)(Cl)]+ (simulated = 609.040). 
 
Solution studies  
For solution studies doubly deionised and ultra-filtered water was obtained from a Milli-
Q RG (Millipore) water purification system. pH-potentiometric measurements were carried out 
at an ionic strength of 0.20 M KCl and at 25.0  0.1 ºC. Carbonate-free KOH solutions of known 
concentrations (ca. 0.2 M) were used as titrant. HCl stock solutions were prepared from 
concentrated HCl and their concentrations were determined by potentiometric titrations using 
the Gran's method.[47] A Mettler Toledo DL50 titrator equipped with a DGi 114-SC electrode 
was used for the pH-metric measurements. The electrode system was calibrated according to 
Irving et al.,[48] the pH-metric readings could therefore be converted into hydrogen ion 
concentration. The water ionization constant, pKw, was 13.75 ± 0.01 under the conditions 
employed. Titrations were performed in the pH range 2.0 – 11.0. Initial volume of the samples 
was 15.00 ml. The metal ion concentrations were varied in the range 1.0 – 3.5 mM and 1:1, 1:2 
and 2:1 metal to ligand ratios were titrated. For the metal ion containing systems a maximum 
waiting time of 15 minutes was applied. The reproducibility of the equilibrium titration points 
included in the evaluation was within 0.005 pH unit. The samples were in all cases completely 
deoxygenated by bubbling purified argon for ca. 15 min prior the measurements. Calculation 
of the stability constants (p,q,r = [RupAqHr]/[Ru]p[A]q[H]r ; where “Ru” stands for [(η6-p-
cym)Ru]2+ and “A” represents the deprotonated forms of the aminohydroxamic acids) of the 
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complexes using the titration curves was attempted by the PSEQUAD or SUPERQUAD 
computer programs.[49-50] During the calculations hydrolysis of [(η6-p-cym)Ru(H2O)3]2+ and its 
interaction with chloride ion were taken into consideration and the following species was 
assumed: [{(6-p-cym)Ru}2(2-OH)2]2+ (log = –7.12), [{(6-p-cym)Ru}2(2-OH)3]+ 
(log = –11.88).[18] 
1H NMR titrations were carried out on a Bruker Avance 360 or 400 NMR instrument at 278 K 
in the presence of 0.20 M KNO3. Chemical shifts are reported in ppm (δH) from sodium 3-
(trimethylsilyl)-propionate (TSP) as internal reference. Titrations were carried out in D2O (99.8 
%) at cRu = 0.01 M in order to register the pH dependence of the chemical shifts of the nuclei 
of hexahapto bonded p-cymene. pH was set up with NaOD or DNO3 in D2O. Individual samples 
were equilibrated at least for 1 h prior measurements. pH* values (direct pH-meter readings in 
a D2O solution of a pH-meter calibrated in H2O according to Irving et al.[48]) were converted to 
pH values measureable at an ionic strength of 0.20 M using the following equation: pH = pH* 
+ 0.40. The interaction of 2 with 9-methylguanine was monitored in D2O using 1:1 and 1:2 
molar ratios at 298 K adopting the method in Ref. [51]. 
For the ESI-MS analysis of the solutions the measurements were performed in water at 0.4 mM 
[(η6-p-cym)Ru(H2O)3]2+ concentration at different pH values and at 1:1 metal ion to ligand 
ratio. Temperature of drying gas (N2) was 180C. The pressure of the nebulizing gas (N2) was 
0.3 bar. The flow rate was 3 μl/min. The spectra were accumulated and recorded by a digitalizer 
at a sampling rate of 2 GHz. DataAnalysis (version 3.4) was used for the calculations.  
 
Cytotoxicity tests 
 
The human ovarian carcinoma A2780, the human breast cancer MCF-7 and human ovarian 
adenocarcinoma SKOV-3 cells were kindly supplied by Professor B. Keppler, University of 
Vienna (Austria). The human colon carcinoma HCT116 cells were a kind gift of Dr. M. 
Brazdova, Institute of Biophysics, Brno (Czech Republic), the human cervix adenocarcinoma 
HeLa cells were obatined from ATCC (Manassas, Virginia, U.S.). The A2780 cells were grown 
in RPMI 1640 medium (PAA; Pasching, Austria) supplemented with streptomycin (100 µg 
mL−1), penicillin (100 U mL−1) (both Sigma, Prague, Czech Republic) and 10% heat inactivated 
fetal bovine serum (PAA; Pasching, Austria). The MCF-7, HeLa, SKOV-3 and HCT-116 cells 
were grown in DMEM medium (PAA; Pasching, Austria) supplemented with gentamycin 
(50 μg mL−1, Serva, Heidelberg, Germany) and 10% heat inactivated fetal bovine serum (PAA; 
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Pasching, Austria). The cells were cultured in a humidified incubator at 37 °C in a 5% CO2 
atmosphere and subcultured 2-3 times a week with an appropriate plating density. 
Cytotoxic effect of compounds 1 and 2 were evaluated by using assays based on the neutral red 
(NR) uptake. The adherent cells were plated out 20 h prior to testing in 96-well tissue culture 
plates at a density of 104 cells/well (A2780) or 4 x 103 cells/well (MCF-7, HeLa, SKOV-3 and 
HCT-116 ) in 100 μL of medium. The cells were treated for 72 h with the compounds at the 
final concentrations in the range of 0 to 0.5 mM in a final volume of 200 μL/well. 
Concentrations of the compounds in the medium during the treatment were verified by 
flameless atomic absorption spectrometry. Thereafter, a viability of the cells was tested by NR 
assay as described previously.[52] Briefly, after the treatment period, 20 µL of a 0.33% solution 
of NR in phosphate buffered saline (PBS) was added to each well with adherent cells and the 
plate was incubated at 37 °C in a humidified 5% CO2 atmosphere for 2 h. Afterwards, the dye 
containing medium was carefully removed and the cells were quickly rinsed with PBS. The 
incorporated dye was then solubilized in 200 µL of 1% acetic acid in 50% ethanol, allowed to 
stand for 10 min at room temperature and the absorbance was measured at λ = 540 nm with 
absorbance reader Synergy MX (Biotek,VT, USA). The background absorbance of the plates 
at 690 nm was also measured and subtracted from 540 nm measurement. The reading values 
were converted to the percentage of the control (percentage cell survival). All experiments were 
repeated at least three times, each repetition made in triplicate. 
 
3. Results and discussion 
 
3.1. Synthesis and characterization of the ligands 
alahaH and alahaH∙HCl were synthesized according to published procedures [41] 
while in the case of -abhaH∙HCl a slightly modified synthetic route was used. For the  and 
derivative the ligands were obtained from the appropriate methylesters and hydroxylamine 
followed by conversion to alahaH∙HCl in the latter case. Pure products were obtained by 
recrystallization from ethanol and checked by NMR exhibiting the expected resonances. For 
abhaH the Z-protected aminobutyric acid was activated with ethylchloroformate and the 
mixed acid anhydride was reacted with O-benzyl-hydroxylamine. The doubly protected 
intermediate was subjected to hydrogenolysis affording the pure product as colourless oil. 
     
3.2. Potentiometric results 
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To check the purity and the exact concentration of the aqueous solutions of the 
aminohydroxamate ligands pH-potentiometric measurements were carried out. As a 
representative example titration curve of alahaH is shown in Fig. 2a. The redetermined 
stepwise protonation constants of the ligands  are summarized in Table 2 and are in excellent 
agreement (within 0.05 log units) with the previous data estimated under identical experimental 
conditions.[53-55] 
Representative titration curves for the [(6-p-cym)Ru(H2O)3]2+ – ligand systems are 
shown in Fig. 2. For - and -alahaH slow complex formation processes were observed in the 
range 3.0 < pH < 7.0 and 4.5 < pH < 7.0, respectively, the usual waiting time (see Experimental) 
was not enough to reach complete pH equilibrium. This is also reflected in the shape of the 
titration curves. At the same time, for the [(6-p-cym)Ru(H2O)3]2+-abhaH system fast 
processes were detected resulting in reliable and reproducible titration curves (Fig. 2c). Despite 
the above facts, analysis and comparison of the sets of titration curves may provide with 
valuable information. For the -alahaH system at 2:1 metal ion to ligand ratio the three 
equivalents of base consumption is consistent with the formation of [Ru2AH–1]2+ (Ru = [(6-p-
cym)Ru]) in which the second metal ion is coordinated via the [N,N] donor set of the ligand. 
This is also supported by the half amount of extra base consumption at 1:1 ratio by pH 5.5. For 
the -alahaH system similar trend is observed, however, the formation of [Ru2AH–1]2+ is 
accompanied by a separate step on the curve above pH ~ 4.5 suggesting smaller stability of this 
complex than that formed with -alahaH. For abhaH the titration curve at 2:1 ratio is more 
complex but still indicates the formation of a [Ru2A] type species. 
The titration curves for all the systems can be fitted well with the models and complexes 
summarized in Table 2 while the calculated concentration distribution curves appear in Fig. 3. 
During model selection [RuAH–1] could be replaced by its dimeric form, [Ru2A2H–2]. It is 
important to emphasize that for the [(6-p-cym)Ru(H2O)3]2+-abhaH system, where stable pH-
metric readings were available, reliable stability constants could be calculated for the 
complexes while in the case of the andalahaH the log values (shown by italic numbers 
in Table 2) should be treated as tentative only. Nevertheless, comparison of the stability 
constants in Table 2 allows to draw some useful conclusions too. 
In all the three systems the complex formation starts with [RuAH]2+ in which the ligands 
coordinate via a hydroxamate [O,O] chelate to the metal ion while the amino groups are 
protonated (see I in Fig. 4 (where, as representative examples, the suggested binding modes 
with -abhaH are shown)). [N,N] coordination mode with protonated hydroxamic function 
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would mean [RuA]+ stoichiometry. Furthermore the logK* values of the three complexes with 
the various ligands (Table 2) referring to the (1) equilibrium process are well comparable with 
each other indicating identical strengths of the coordinating donor atom sets supporting thus the 
hydroxamate coordination mode.  
Ru2+ + H2A+ = [RuAH]2+ + H+    (1) 
With increasing pH slow complex formation processes were detected in the systems 
containing the - and -alahaH, but not with abhaH ligand. Speciation curves (Fig. 3 A-C) 
indicate the binding of a second metal ion in each system resulting in the formation of [Ru2AH–
1]2+ in agreement with the three equivalents of base consumptions in the titration curves of each 
ligand at 2:1 metal ion to ligand ratio. This complex stoichiometry can be rationalized with the 
deprotonation of the hydroxamate-NH and the ammonium group as it is illustrated by II in Fig. 
4. Although the logRu2AH-1 values can only be considered as tentative for the - and -alahaH 
ligand, the decreasing trend in the →  direction clearly supports the decreased stability of 
the [N,N] chelated species due to the increasing chelate size. Parallel with the formation of 
[Ru2AH–1]2+, further increase in pH results in the displacement of the hydroxamate [O,O] 
coordinated metal ion with the formation of [RuA]+. In principle, in the [RuA]+ species the 
ligands can coordinate by [O,O] fashion with deprotonation of the water molecule at the third 
coordination site, however, the rather low pKRuAH values, especially for the  and  derivative 
(Table 2), seem not to support this binding mode. It is more likely that these values belong to 
the metal ion assisted deprotonation and coordination of the ammonium group, resulting in the 
formation of III (Fig. 4) as the most plausible solution structure, but the formation of [Ru2A2]2+ 
with [(O,O)(NH2)] coordination mode of the ligands can not be ruled out either. In all systems 
further deprotonation yields [RuAH–1]x (x = 1-2) species that are indistinguishable by pH-
potentiometry from each other. [RuAH–1] may be a mixed hydroxido complex (IV, Fig. 4), but 
ESI MS results also support the formation of the appropriate dinuclear complexes, [Ru2A2H–2] 
(vide infra). These species may consist of two [N,N] coordinated entities bridged by the 
hydroxamate oxygens of the ligands (V, Fig. 4). 
 
3.2. ESI-TOF-MS results 
 
ESI-TOF-MS measurements also provided valuable information in the identification of 
the species present in solution. As a representative example MS spectrum acquired in the [(6-
p-cym)Ru(H2O)3]2+–abhaH system at 1:1 ratio is shown in Fig. 5. Fig. 5 reveals that [RuA]+ 
and [Ru2(AH–1)Cl]+ are the major complexes at pH = 6.07 supporting thus the pH-
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potentiometric results. The identified species existing at various ratios and pH values are 
summarized in Table 3 while, as a representative example, the estimated and observed isotope 
pattern for [Ru2A2H–2] + K+ in the abhaH system can be seen in Fig. S2. For all the species 
in Table 3 the correct isotopic pattern was found proving in this way the identity of the 
complexes. 
 
 
3.3. NMR results 
 Complex formation was also monitored by 1H NMR spectroscopy. As a representative 
example, pH-dependence of the aromatic part of the spectra recorded in the [(6-p-
cym)Ru(H2O)3]2+– abhaH system at 1:1 metal ion to ligand ratio are shown in Fig. 6. At pH 
= 2.78 beside the doublets of the p-cymene ring hydrogens belonging to [(6-p-
cym)Ru(H2O)3]2+ (5.73 and 5.98 ppm) and [(6-p-cym)Ru(H2O)2Cl]+ (5.63 and 5.85 ppm) 
species[20], a new pair of doublets also appears corresponding most likely to [RuAH]2+. In 
accordance with the speciation in Fig. 3c at pH ~ 5 this becomes the predominant complex. On 
increasing the pH, small upfield shift of the resonances of [RuAH]2+ is consistent with a slight 
change in the coordination environment of the metal ion, e.g. deprotonation of the coordinating 
water, resulting in the partial formation of [RuA]+ (= [RuAH(OH)]+). This is plausible for the 
-abhaH system as the pKRuAH is rather high here compared to the other two ligands. Due to the 
fast exchange processes on the NMR time scale, the resonances of these two species appear as 
an averaged signal in the spectrum. The additional two sets of new doublets at pH = 6.23 may 
belong to two p-cym units being in different chemical environments in [Ru2AH–1]2+. Above pH 
~ 7 the spectra become rather complex. It is clear, however, that significant hydrolysis of the 
metal ion resulting in the formation of [{Ru(6-p-cym)}2(2-OH)3]+ (5.18 and 5.38 ppm)[20] 
does not occur up to pH = 11 in agreement with the speciation (Fig. 3c). Homonuclear 2D NMR 
experiments were also performed to gain additional information from the complex formation 
above pH ~ 7. While in the aromatic region of 1H-1H COSY spectrum (Fig. 7, red contour plot) 
cross-peaks can only be seen between ortho protons, in the same part of 1H-1H TOCSY 
spectrum (Fig. 7, black contour plot) with long mixing time (120 ms) cross-peaks can also be 
seen between protons in meta and para position to each other. The careful evaluation of the 
TOCSY spectrum together with the COSY spectrum on the sample of pH = 8.52 (Fig. 7) has 
revealed that three main, individual [(6-p-cym)Ru]2+-containing spin systems existed in which 
all the p-cymene ring hydrogens became magnetically non-equivalent. This strongly suggests 
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that both [RuA]+ and [RuAH–1]x (x = 1–2) in the form of binding isomers or dimers, as it is 
proposed in Fig. 4, may be present. 
 In order to model the interaction with DNA the binding capability of 2 with 9-
methylguanine in aqueous solution was studied. As a representative example time dependence 
of the 1H NMR spectra obtained is presented in Fig. 8. Since compound 2 does not have any 
resonances above 6 ppm, all signals shown in Figure 8 must be due to different guanine adducts 
(represented by the H8 resonances of 9-methylguanine). For the free ligand the H8 resonance 
is observed at 7.74 ppm (not shown here) at pH 7.0 in accordance with previous results.[51] At 
this resonance in Fig. 8 a broad signal of the free ligand is present (probably due to paramagnetic 
impurities in the NMR solvent). The other major resonances in the range 7.60–8.50 ppm clearly 
support that the guanine derivative interacts with 2. The number of new signals indicate that, 
as a result of the binding of 9-methylguanine to the half-sandwich type metal core, 
diastereomers can be formed. Furthermore, the dissociation of the dinuclear metal complex and 
the formation of various adducts with the ligand can not be ruled out either. The binding is also 
supported by literature data where downfield shift of the H8 resonances was found for [Ru(6-
bip)(en)]2+ (bip = biphenyl, en = ethylenediamine) containing an (N,N) chelator[56] while a 
slight upfield shift was detected for [Ru(6-p-cym)(acac)Cl] (acac = acetylacetonate) 
containing an (O,O) chelating set[57] upon reacting with 9-ethylguanine. Regarding the rate of 
the interaction the spectra suggest that this is fast (in accordance with earlier findings[56,57]) as 
no significant change in the ratio of the major signals in the function of time can be seen, 
however, two additional minor species also seem to be formed at a much slower rate.       
 
3.4 Solid state structures 
 To obtain further proof for the existence and binding mode of the dinuclear complex 
suggested by pH-potentiometry and detected by ESI MS, solid state studies were also carried 
out. Treatment of the aqueous solutions containing the metal ion and -alahaH with bromide 
or BF4– anions afforded dinuclear complexes as red crystalline solids in modest yield. The 
compounds were characterized by elemental analysis, NMR, IR and ESI-MS methods (see 2.4 
part for details). NMR showed the expected resonances of the methine and methyl protons of 
the ligand. IR spectra of the novel aminohydroxamate complexes exhibited a new sharp band 
at 1578 cm–1 compared to those of [(η6-p-cym)RuCl2]2 precursor which was assigned to the CO 
of the coordinating hydroxamates. The BF4– anion in 2 was indicated by the chatacteristic 
streching at 1060 cm–1. 
13 
 
Single crystal X-ray diffraction studies also revealed that 1 and 2 are indeed dinuclear 
ruthenium complexes in the solid state, too (Figs. 9 and 10). The structures of 1 and 2 are highly 
similar ones (Fig. S1) with some difference at the p-cym moiety only. Regarding other platium 
group metals search in the Cambridge Structural Database (Ver. 5.36 Update May, 2015.)[58] 
revealed no similar binding mode with bridging hydroxamate ligand among Ru, Rh, Ir, Os, Pd 
complexes. Only the platinum complex of pyridine-2-hydroxamate in 2-pyridine-2-
hydroximato-N,N',O,O')-bis(cis-diammine-platinum(II)) had analogous [N,N][O,O] 
coordination geometry[59] but due to the pyridine moiety the structures are less comparable. 
Although this coordination fashion is quite abundant among copper and nickel hydroxamato 
compounds they are multinuclear rather than dinuclear complexes. In 1 and 2 the Ru–N and 
Ru–O distances for the hydroxamato ligands are in the expected range of 2.04–2.15 Å. The 
distance of the oxygen atom of the coordinated water molecule to the ruthenium center (Ru(1)–
O(1)) is 2.204(5) Å and 2.191(5) Å for complex 1 and 2, respectively. Due to steric 
requirements of the bulky p-cym ligand the angle of the mean planes of C-C-N-N-Ru and C-N-
O-O-Ru is 17o for 1 and 16o for 2. These are quite high values considering all the similarly 
[N,N][O,O] coordinated bridging hydroxamato complexes. Search of the CSD gave 106 hits 
for 2-aminohydroxamato or pyridine-2-hydroxamato complexes with [N,N] and [O,O] 
coordination in multinuclear metal complexes but only 25 hits remained when the angle of the 
coordination planes was limited into the range of 14o – 25o. These hits are pentameric copper, 
nickel or zinc hydroximato metallacrown complexes in which the cavity is occupied by a 
lanthanide ion resulting in similarly high steric constrains on the C-C-N-N and C-N-O-O planes 
of the bridging hydroximate-derivative ligand. Further bond distance and bond angle data can 
be found in the caption of Figs. 9 and 10. As alahaH in this study was racemic and two new 
stereogenic centers were formed on the Ru atoms upon coordination of the ligands we have a 
diastereomeric pair in the lattice forming a centrosymmetric space group. In this case the 
relative configuration of the stereogenic centers can be determined. Similar chiral-at-metal 
complexes have paramount importance in homogeneous catalytic processes.[60] However, there 
is no IUPAC recommendation for the nomenclature of the chirality of metal-arene sandwich or 
half-sandwich complexes. Using an analogy[61] to the Cahn-Ingold-Prelog nomenclature 
suggests to use the pseudoatom convention by replacing the p-cym ligand with a pseudoatom 
with an atomic weight of 6 x 12 = 72 amu. Although the complexes 1 and 2 are homochiral 
ones (Fig. S1) this convention results in change in the priority rules causing opposite assignment 
for Ru(2). Hence the relative configuration of complex 1 is S*C(1),R*Ru(1),R*Ru(2) while that of 
complex 2 is S*C(1),R*Ru(1),S*Ru(2). 
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Cytotoxicity in cancer cells 
 
The in vitro anti-cancer chemotherapeutic potential of complexes 1 and 2 towards a set of 
various human cancer cell lines (A2780, MCF-7, HeLa, SKOV-3 and HCT-116) was also 
tested. To determine cytotoxic effect of the compounds NR assay have been employed. This 
assay is based on the ability of viable cells to incorporate and bind the dye in lysosomes by an 
active metabolic process. The results clearly showed that the complexes tested in this work 
caused very low or insignificant cytotoxic effect (Fig. 11) even in the highest concentration 
tested in this work (0.5 mM). In contrast, cisplatin displayed a significant reduction in viability 
of the cells under the same conditions with the mean IC50 values of 1.8 ± 0.2 μM, 8.2 ± 1.0 μM, 
1.9 ± 0.1 μM, 12.1± 2.1 μM and 7.4 ± 0.7 μM for A2780, MCF-7, HeLa, Skov-3, and HCT-
116 cells, respectively. Thus, compounds 1 and 2 expressed cytotoxic activity more than two 
order of magnitude lower than cisplatin, even in those cancer cells inherently resistant to 
cisplatin. 
 
4. Conclusions 
Previously simple hydroxamates were proven to be effective binders for half-sandwich 
type Ru(II) at pH = 7.4[18], but high thermodynamic stability of the complexes was accompanied 
by labile kinetic behaviour. These fast ligand exchange processes seemed to count for 
ineffective anticancer activity found on human-derived A2780 and A2780R cell lines.  
Our results in this study indicate that the presence of an amino group in chelatable 
position to the primary hydroxamate function in aminohydroxamates provides effective ligands 
for binding a half-sandwich type Ru(II). These molecules were shown to be capable of 
preventing the metal ion from hydrolysis up to pH ~ 11 and can also bind a second metal ion. 
Partially slow complex formation processes under weakly acidic conditions for the  and  but 
not for the  derivative seem to be correlated with the size of the (N,N) chelate that can also be 
found with these ligands beside the (O,O) hydroxamate one. This more inert kinetic behaviour 
made especially -alaha a promising candidate for biological tests. Moreover, 2 was shown to 
react with 9-methylguanine (as a DNA model) in a fast reaction. However, the results of the 
cell line studies indicated that 1 and 2 both sharing very similar binding architecture are not 
effective in the micromolar concentration range against the A2780, MCF-7, HeLa, Skov-3, and 
HCT-116 cell lines. 
15 
 
 
Acknowledgments 
The authors thank members of the EU COST Action CM1105 for motivating 
discussions. This work was supported by the Hungarian Scientific Research Fund (OTKA 
K112317 and NK105691). The research of J.K. and T.R-M. was also supported by the Ministry 
of Education, Youth and Sports of the CR (Grant LH 14317) and by Palacky University in 
Olomouc (IGAPrF2015025). 
 
References  
 
[1] A.M. Albrecht-Gary, A.L. Crumbliss, Metal Ions in Biological Systems 1998, 35, 239-
327. 
[2] H. Boukhalfa, A.L. Crumbliss, Biometals 2002, 15, 325-339. 
[3] C.J. Marmion, J.P. Parker, K.B. Nolan, Hydroxamic Acids: An Important Class of 
Metalloenzyme Inhibitors. In: Jan Reedijk and Kenneth Poeppelmeier, Eds, Elsevier, 
Comprehensive Inorganic Chemistry II: From Elements to Applications, 2013, 3, 684-
708. 
[4] E.M.F. Muri, M.J. Nieto, R.D. Sindelar, J.S. Williamson, Curr. Med. Chem. 2002, 
9, 1631-1653. 
[5] P.A. Marks, Oncogene 2007, 26, 1351–1356.  
[6]  M. Melchart, P.J. Sadler, in Bioorganometallics, ed. G. Jaouen, Wiley-VCH, Weinheim, 
Germany, 2006, p. 39-64. 
[7] B. Therrien, Coord. Chem. Rev. 2009, 253, 493–519. 
[8]  P.C.A. Bruijnincx, P.J. Sadler, Adv. Inorg. Chem. 2009, 61, 1-62. 
[9]  G. Süss-Fink, Dalton Trans. 2010, 39, 1673-1688. 
[10] I. Bratsos, T. Gianferrara, E. Alessio, C.G. Hartinger, M.A. Jakupec, B.K. Keppler, in 
Bioinorganic Medicinal Chemistry, ed. E. Alessio, Wiley-VCH, Weinheim, Germany, 
2011, p. 160-164. 
[11] H. Chen, J.A. Parkinson, R.E. Morris, P.J. Sadler, J. Am. Chem. Soc. 2003, 125, 173-186. 
[12] O. Novakova, H. Chen, O. Vrana, A. Rodger, P. J. Sadler, V. Brabec, Biochemistry, 2003, 
42, 11544-11-554. 
[13] H-K. Liu, S.J. Berners-Price, F. Wang, J.A. Parkinson, J. Xu, J. Bella, P.J. Sadler, Angew. 
Chem. Int. Ed. Engl. 2006, 45, 8153-8156. 
[14] A.M. Pizarro, P.J. Sadler, Biochimie, 2009, 91, 1198-1211, and references therein. 
[15] V. Moreno, M. Font-Bardia, T. Calvet, J. Lorenzo, F.X. Avilés, M.H. Garcia, T.S. Morais, 
A. Valente, M.P. Robalo, J. Inorg. Biochem., 2011, 105, 241-249.  
[16] A.I. Tomaz, T. Jakusch, T.S. Morais, F. Marques, R.F.M. de Almeida, F. Mendes, É.A. 
Enyedy, I. Santos, J. Costa Pessoa, T. Kiss, M.H. Garcia, J. Inorg. Biochem., 2012, 117, 
261-269. 
[17] T.S. Morais, F. Santos, L. Côrte-Real, F. Marques, M.P. Robalo, P.J.A. Madeira, M.H. 
Garcia, J. Inorg. Biochem. 2013, 122, 8-17. 
[18] P. Buglyó, E. Farkas, Dalton Trans. 2009, 8063-8070. 
[19] L. Bíró, E. Farkas, P. Buglyó, Dalton Trans. 2010, 39, 10272-10278. 
[20] L. Bíró, E. Farkas, P. Buglyó, Dalton Trans. 2012, 41, 285-291. 
[21] L. Bíró, D. Hüse, A.C. Bényei, P. Buglyó, J. Inorg. Biochem. 2012, 116, 116-125. 
16 
 
[22] É.A. Enyedy, G.M. Bognár, T. Kiss, M. Hanif, C.G. Hartinger, J. Organomet. Chem. 
2013, 734, 38-44. 
[23] L. Bíró, E. Balogh, P. Buglyó,  J. Organomet. Chem. 2013, 734, 61-68. 
[24] A. Kurzwernhart, W. Kandioller, É.A. Enyedy, M.Novak, M.A. Jakupec, B.K. Keppler,  
C.G. Hartinger, Dalton Trans. 2013, 42, 6193-6202. 
[25] É.A. Enyedy, É. Sija, T. Jakusch, C.G. Hartinger, W. Kandioller, B.K. Keppler, T. Kiss, 
J. Inorg. Biochem. 2013, 127, 161-168. 
[26] D. Hüse, L. Bíró, J. Patalenszki, A.C. Bényei, P. Buglyó, Eur. J. Inorg. Chem. 2014, 
5204-5216. 
[27] É. Sija, C.G. Hartinger, B.K. Keppler, T. Kiss, É.A. Enyedy, Polyhedron 2014, 67, 51-
58. 
[28] Zs. Bihari, Z. Nagy, P. Buglyó, J. Organomet. Chem. 2015, 782, 82-88. 
[29] J. Patalenszki, L. Bíró, A.C. Bényei, T.R. Muchova, J. Kasparkova, P. Buglyó, RSC Adv. 
2015, 5, 8094-8107. 
[30] A.J. Godó, A.C. Bényei, B. Duff, D.A. Egan, P. Buglyó, RSC Adv. 2012, 2, 1486–1495. 
[31] A.F.A. Peacock, A. Habtemariam, R. Fernandez, V. Walland, F.P.A. Fabbiani, S. 
Parsons, R.E. Aird, D.I. Jodrell, P.J. Sadler, J. Am. Chem. Soc. 2006, 128, 1739-1748.   
[32] B. Kurzak, H. Kozlowski, E. Farkas, Coord, Chem. Rev. 1992, 114, 169-200. 
[33] B. Kurzak, E. Farkas, J. Coord. Chem. 1993, 28, 203-207. 
[34] E. Farkas, K. Megyeri, L. Somsák, L. Kovács, J. Inorg. Biochem. 1998, 70, 41-47. 
[35] E. Farkas, H. Csóka, G. Bell, D.A. Brown, L.P. Cuffe, N.J. Fitzpatrick, W.K. Glass, W. 
Errington, T.J. Kemp, J. Chem. Soc., Dalton Trans. 1999, 2789-2794. 
[36] P. O`Sullivan, J.D. Glennon, E. Farkas, T. Kiss, J. Coord. Chem. 1996, 38, 271-280. 
[37] É.A. Enyedy, H. Csóka, I. Lázár, G. Micera, E. Garribba, E. Farkas, J. Chem. Soc., Dalton 
Trans. 2002, 2632-2640. 
[38] B. Kurzak, E. Farkas, T. Glowiak, H. Kozlowski, J. Chem. Soc., Dalton Trans. 1991, 163-
167. 
[39] V.L. Pecoraro, A.J. Stemmler, B.R. Gibney, J.J. Bodwin, H. Wang, J.W. Kampf, A. 
Barwinski in Metallacrowns: A New Class of Molecular Recogntition Agents, Progress 
in Inorganic Chemistry, ed.: K. D. Karlin, John Wiley, New York, 1997, vol. 45. 
[40] D.D. Perrin, W.L.F. Armarego, Purification of Laboratory Chemicals, 3rd ed., Pergamon, 
Oxford, 1988. 
[41] A.H. Blatt, Organic Synthesis Collection 1943, Wiley, New York, Vol. 2, p. 67. 
[42] M.A. Bennett, A.K. Smith, J. Chem. Soc., Dalton Trans. 1974, 233–241. 
[43] A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, J. Appl. Cryst. 1993, 26, 
343-350. 
[44] G.M. Sheldrick, Acta Cryst. 2008, A64, 112-122. 
[45] L.J. Farrugia, J. Appl. Cryst. 1999, 32, 837-838. 
[46] S.P. Westrip, J. Appl. Cryst., 2010, 43, 920-925. 
[47] G. Gran, Acta Chem. Scand., 1950, 4, 559–577. 
[48] H.M. Irving, M.G. Miles, L.D. Pettit, Anal. Chim. Acta, 1967, 38, 475–488. 
[49] L. Zékány and I. Nagypál, in: D. Leggett (Ed.), Computational Methods for the 
Determination of Stability Constants, Plenum, New York (1985). 
[50] P. Gans, A. Sabatini, A. Vacca, J. Chem Soc., Dalton Trans. 1985, 1195–1200.  
[51] N. Busto, J. Valladolid, M. Martínez-Alonso, H.J. Lozano, F.A. Jalón, B.R. Manzano, 
A.M. Rodríguez, M.C. Carrión, T. Biver, J.M. Leal, G. Espino, B. García, Inorg. Chem., 
2013, 52, 9962-9974. 
[52] V. Novohradsky, L. Zerzankova, J. Stepankova, A. Kisova, H. Kostrhunova, Z. Liu, P.J. 
Sadler, J. Kasparkova, V. Brabec, Metallomics, 2014, 6, 1491-1501. 
[53] E. Farkas, T. Kiss, B. Kurzak, J. Chem. Soc., Perkin Trans. 1990, 2, 1255-1257. 
17 
 
[54] D. Bátka, Ph.D. Thesis, University of Debrecen, 2007. 
[55] O. Szabó, Ph.D. Thesis, University of Debrecen, 2013. 
[56] H. Chen, J.A. Parkinson, S. Parsons, R.A. Coxall, R.O. Gould, P.J. Sadler, J. Am. Chem. 
Soc., 2002, 124, 3064-3082. 
[57] R. Fernández, M. Melchart, A. Habtemariam, S. Parsons, P.J. Sadler, Chem. Eur. J., 
2004, 10, 5173-5179. 
[58] F.R. Allen, Acta Crystallogr., Sect. B: Struct. Sci., 2002, 58, 380-388. 
[59] D. Griffith, K. Lyssenko, P. Jensen, P.E.  Kruger, C.J. Marmion, Dalton Trans., 2005, 
956-961. 
[60] Chirality in Transition Metal Chemistry: Molecules, Supramolecular Assemblies and 
Materials, Eds. H. Amouri and M. Gruselle, Wiley, 2008, pp. 65-97. 
[61] Bioorganometallic Chemistry Applications in Drug Discovery, Biocatalysis, and 
Imaging, Eds. G. Jaouen and M. Salmain, Wiley, 2015, pp. 89-90. 
 
 
